Key Players
Competitive Landscape
A laboratory ordering an established strain and a sponsor commissioning a disease-model study need different forms of supplier support, creating several competitive positions within animal models. The strain supplier must provide defined identity and health characteristics, while a specialist development program can require genetic-model expertise or an associated preclinical service. Those relationships can produce repeat business when the model remains useful across related investigations and its characteristics are reproducible. Evaluation of non-animal approaches also changes the questions suppliers need to address, because customers increasingly compare methods for a particular evidentiary purpose. [1][2][3] Participants able to explain model suitability and provide practical characterization can contribute to that decision across the research institutions and development programs they serve. [4]
Regulatory and industry developments mapped to drivers, trends and opportunities (2026 to 2036)
Table 10: Regulatory and industry developments in Animal Model Market
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| FDA described its new-approach-methodologies terminology initiative in September 2026. [1] | Research programs need clear language for the methods used to produce evidence. | Non-animal approaches are discussed alongside nonhuman in-vivo methods without changing evidentiary standards. | Providers can explain the specific evidentiary purpose served by an available model or method. |
| The European Commission adopted its chemical-safety animal-testing phase-out roadmap in June 2026. [2] | Chemical safety assessment is moving toward suitable alternatives to animal testing. | A defined regulatory application guides the transition described in the roadmap. | Specialist providers can support method selection for the particular assessment being conducted. |
| MEXT published institutional animal-experimentation implementation-survey resources in August 2026. [4] | Research institutions need practical implementation of their animal-experimentation framework. | Institutional practice is examined alongside published fundamental guidance. | Model and service suppliers can support defined research requirements with clear characterization and documentation. |
Source: US Food and Drug Administration; European Commission; Japan Ministry of Education, Culture, Sports, Science and Technology.
How do model supply and commissioned research create different supplier roles?
Charles River Laboratories and Taconic Biosciences combine model supply with associated services, while The Jackson Laboratory provides defined mouse-model resources and research support. genOway addresses genetically engineered models, and Crown Bioscience serves preclinical disease-model investigations. A laboratory ordering an established strain therefore makes a different purchase from a sponsor commissioning a specialist study, with the model's biological characteristics and the requested research work determining which supplier capabilities are relevant.
What do current method initiatives establish about the competitive setting?
FDA's terminology initiative recognizes non-animal approaches alongside nonhuman in-vivo methods and states that it does not prescribe a method or change evidentiary standards. [1] The European Commission's roadmap addresses the defined field of chemical safety assessment. [2] These initiatives create a more specific discussion about which method answers an evidentiary question, with the 3Rs providing an established framework for considering replacement, reduction and refinement in animal research. [3]
What should a research institution establish before selecting a model provider?
A research institution needs a model whose identity and biological characteristics fit the question being investigated, together with the health and supply information required to use it reproducibly. A commissioned study adds requirements concerning the work performed and the resulting evidence. Consideration of alternatives also belongs within that decision, following the 3Rs and the applicable institutional framework, rather than assuming that one model or method suits every investigation. [3][4]
How could supplier relationships change across the forecast period?
Repeated use of a characterized model can support an ongoing supplier relationship when related investigations need comparable biological starting conditions. Specialist genetic-model and disease-study services provide additional routes to that relationship. As customers examine non-animal approaches for particular evidentiary purposes, providers will also need to explain where their model contributes useful information. FDA's terminology initiative and the European chemical-safety roadmap illustrate the importance of making that assessment at the method and application level. [1][2]
Representative Company Overview
Table 11: Representative company overview for animal model market
| Company | Positioning | Recent development or documented offering |
|---|---|---|
| Charles River Laboratories | Research models and associated preclinical services | Research models and associated preclinical services provide options ranging from model purchase to supported investigations, with the requested study determining the appropriate service scope. |
| The Jackson Laboratory | Defined mouse models and research support | Defined mouse-model resources support investigations needing characterized starting material, making model identity and its relevance to the scientific question important purchasing considerations. |
| Taconic Biosciences | Rodent research models and model services | Rodent models and related services address established and specialized requirements, with selection dependent on the specified biological characteristics and research schedule. |
| genOway | Genetically engineered research models | Genetically engineered models address defined biological questions, requiring the proposed model characteristics to be connected with the investigation the customer intends to conduct. |
| Crown Bioscience | Preclinical disease models and research services | Disease-model research services support preclinical development work, with the relevant offering determined by the evidence and study activities needed for the program. |
Research Methodology
The research examines animal models through the biological question, the characteristics of the model and the information required by the investigation. Official US, European, UK and Japanese resources support the discussion of alternatives, welfare principles and institutional arrangements, with specific initiatives retained within their published scope. [1][2][3][4] Species, end users and applications are assessed separately, while company comparisons distinguish strain supply, specialized development and preclinical services. Market values use 2025 as the historical reference and cover 2026 to 2036, with country profiles relating projected demand to local research conditions. The analysis recognizes that appropriate alternatives can change the method selected for particular tasks, while characterized animal models continue to address the research questions for which their biological attributes remain useful.
